Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves first-in-class cholesterol-lowering agent

Oct. 29, 2002

Sanguine to enter agreement with City of Hope for PHER-02

Oct. 29, 2002

Orally available prodrugs of SGLT-2 inhibitors covered by Kissei patent

Oct. 29, 2002

Novel melanocortin MC4 receptor agonists under study at Merck

Oct. 29, 2002

Reduction of serum urate levels reported for febuxostat in gout patients

Oct. 28, 2002

Merck KGaA and Kos establish licensing agreement for Niaspan and Advicor

Oct. 28, 2002

Novel vitamin D analogues for calcium metabolic disorders covered by Chugai patent

Oct. 28, 2002

Sumitomo researchers identify novel inhibitors of farnesoid X receptor transcription

Oct. 28, 2002

New aldose reductase inhibitors in Sankyo development pipeline

Oct. 28, 2002

Amylin withdraws Symlin MAA in E.U. with plans to resubmit

Oct. 25, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...